Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects

Archives of Gynecology and Obstetrics

Volumn 275, Issue 5, 2007, Pages 335-339

  Tugrul, Semih ^a,b   Yildirim, Gazi ^a   Pekin, Oya ^a   Uslu, Hüsamettin ^a   Kutlu, Tayfun ^a   Eren, Sadiye ^a  

^a Zeynep Kamil Maternity Hospital   (Turkey)

^b NONE   (Turkey)

Author keywords

Cholesterol; Medroxyprogesterone acetate; Menopause; Norethindrone acetate

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; SIDE EFFECT; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; BODY WEIGHT; CHOLESTEROL; CONTRACEPTIVE AGENTS, FEMALE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPOPROTEINS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; NORETHINDRONE; PROSPECTIVE STUDIES; TRIGLYCERIDES;

EID: 33947532168     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-006-0265-5     Document Type: Article

References (15)

1. Jorma H, Raija V, Ahomaki SM, Kainulainen P, Vitanen A, Timonen U (2000) Optimizing continuous combined hormone replacement therapy for postmenopausal women: a comparision of six different treatment regimens. Am J Obstet Gynecol 182:560-567
2. Notelovitz M, Cassel D, Hille D (2000) Efficacy of of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. Am J Obstet gynecol 182:7-12
3. Cooper A, Whitehead M (1995) Menopause: refining benefits and risk of hormone replacement therapy. Curr Opin Obstet Gynecol 7:214-219
4. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB (2000) Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283(14):1845-1852
5. The Writing Group for the PEPI Trial (1995) Effect of hormone replacement therapy on endometrial hystology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 273(3):199-208
6. Christiansen C, Riis BJ (1990) Five years with continuous combined estrogen/progestogen thrapy. Effects on calcium metabolism, lipoproteins and bleeding pattern. Br J Obstet Gynecol 97:1087
7. Hulley S, Grady D, Bush T, Furberg C, Herrington DB, Vittinghoff E, for the Heart and Estrogen/Progestin Replacement Study (HERS) Researche Group (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary hearth disease in postmenopausal women. JAMA 280:605-613
8. Basta A, Szczudrawa A, Sempka A, Peszek W, Bogdanowicz M (2001) A clinical assessment of a 3 month replacement therapy effectiveness with low norethisterone acetate (Activelle) in postmenopausal women. Przegl Lek 58(6):471-473
9. Johnson JV, Davidson M, Archer D, Bachmann G (2002) Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy. Menopause 9(1):16-22
10. Samsioe G, Li C, Borgfeldt C, Wilawan K, Aberg A, Larsen S (2002) Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate. Menopause 9(5):335-342
11. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349(6):523-534
12. Wing R, Matthews K, Kuller L, Meilahn EN, Plantinga PL (1990) Weight gain at the time of menopause. Arch Intern Med 151:97-101
13. Kritz Silverstein D, Barrett Cannor E (1996) Long term postmenopausal hormone use, obesity and fat distribution in older women. JAMA 27:46
14. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK, Greendale GA, for the Postmenopausal Estrogen/Progestin Interventions Study Investigators (1997) Effect of postmenopausal hormone therapy on body weight and waist and hip girths. J Clin Endocrinol Metab 82:1549
15. Baerug U, Winge T, Nordland G, Faber-Swensson E, Heldaas K, Norling B, Larsen S, Arce JC (1998) Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1(3):219-228